Eylward Susan 4

What Happened
Susan Eylward, General Counsel and Corporate Secretary of Imunon, received 14,696 shares on June 25, 2026 as a stock award (valued at $1.72/share, ~$25,277) issued in lieu of 50% of her 2025 cash bonus. Four days later (June 29, 2026) she sold 11,800 shares in an open-market transaction at a weighted average price of $1.752/share (prices ranged $1.73–$1.80), for proceeds of about $20,674. The transactions resulted in a net increase of 2,896 shares held by Eylward (14,696 acquired minus 11,800 sold). The award is an acquisition (A) and the sale is an open-market sale (S).

Key Details

• Transaction dates and prices:
  • 2026-06-25: Award of 14,696 shares at $1.72/share (~$25,277). (Footnote F1)
  • 2026-06-29: Sale of 11,800 shares, weighted average $1.752/share (~$20,674); sale prices ranged $1.73–$1.80. (Footnote F2)
• Net change: +2,896 shares overall from these two transactions.
• Shares owned after transaction: not disclosed in the filing.
• Footnotes:
  • F1: Stock granted in lieu of cash for 50% of 2025 annual cash bonus.
  • F2: Weighted average sale price $1.752; seller can provide breakdown of shares sold at each price on request.
• Timeliness: Form 4 filed June 29, 2026. Transactions were reported timely (no late filing indicated).

Context

• The award was compensation-related (bonus paid in stock), not an open-market buy; such grants are common for executive compensation and do not by themselves signal buy/sell intent. The subsequent sale was an open-market disposition of some of those shares.
• No option exercises, gifts, 10b5-1 plan, or tax-withholding sale were disclosed on this Form 4.